Akoya Biosciences Inc (NASDAQ: AKYA)’s stock price has gone rise by 4.00 in comparison to its previous close of 1.25, however, the company has experienced a -1.52% decrease in its stock price over the last five trading days. prnewswire.com reported 2025-05-23 that RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ — Kent Lake PR LLC (“Kent Lake”), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued the following statement regarding the Company’s Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences’ (“Akoya”) (NASDAQ: AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. “Quanterix’s amended merger terms (the “Amended Merger Agreement”), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya.
Is It Worth Investing in Akoya Biosciences Inc (NASDAQ: AKYA) Right Now?
Additionally, the 36-month beta value for AKYA is 1.35. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for AKYA is 20.84M and currently, short sellers hold a 13.64% ratio of that float. The average trading volume of AKYA on June 19, 2025 was 462.52K shares.
AKYA’s Market Performance
AKYA stock saw an increase of -1.52% in the past week, with a monthly gain of 23.81% and a quarterly increase of -22.62%. The volatility ratio for the week is 3.24%, and the volatility levels for the last 30 days are 6.82% for Akoya Biosciences Inc (AKYA). The simple moving average for the past 20 days is 4.97% for AKYA’s stock, with a -38.53% simple moving average for the past 200 days.
Analysts’ Opinion of AKYA
Many brokerage firms have already submitted their reports for AKYA stocks, with Craig Hallum repeating the rating for AKYA by listing it as a “Hold.” The predicted price for AKYA in the upcoming period, according to Craig Hallum is $5 based on the research report published on November 15, 2024 of the previous year 2024.
AKYA Trading at 9.52% from the 50-Day Moving Average
After a stumble in the market that brought AKYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.99% of loss for the given period.
Stock Fundamentals for AKYA
Current profitability levels for the company are sitting at:
- -0.48 for the present operating margin
- 0.62 for the gross margin
The net margin for Akoya Biosciences Inc stands at -0.59. The total capital return value is set at -8.44. Equity return is now at value -354.27, with -35.55 for asset returns.
Based on Akoya Biosciences Inc (AKYA), the company’s capital structure generated 1.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.36. The debt to equity ratio resting at -14.22. The interest coverage ratio of the stock is -7.24.
Currently, EBITDA for the company is -37.14 million with net debt to EBITDA at -1.99. When we switch over and look at the enterprise to sales, we see a ratio of 1.6. The receivables turnover for the company is 6.81for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.61.
Conclusion
In conclusion, Akoya Biosciences Inc (AKYA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
